Inovio Pharmaceuticals, Inc. (INO) Tops Q1 Loss Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- Wall Street ends lower, off record highs, as Treasury yields climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
Tweet
Share
E-mailGet Alerts INO Hot Sheet
Price: $1.16 +2.65%
EPS Growth %: +75.9%
Financial Fact:
License fee and milestone revenue: 2.33M
Today's EPS Names:
AEHR, VFS, CMTL, More
EPS Growth %: +75.9%
Financial Fact:
License fee and milestone revenue: 2.33M
Today's EPS Names:
AEHR, VFS, CMTL, More
Join SI Premium – FREE
Inovio Pharmaceuticals, Inc. (NYSE: INO) reported Q1 EPS of $0.00, $0.04 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $1.1 million versus the consensus estimate of $1.08 million.
For earnings history and earnings-related data on Inovio Pharmaceuticals, Inc. (INO) click here.
For earnings history and earnings-related data on Inovio Pharmaceuticals, Inc. (INO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Some Said Inflation Risks Had Become More Skewed To Upside - FOMC Minutes
- Hess Midstream stock drops on Chevron restructuring and lower 2027 outlook
- Parabolic reports preliminary Q3 2026 revenue of $4.7 million
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
